Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01602406
Title Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

stomach cancer

Her2-receptor positive breast cancer

Therapies

Elgemtumab + Trastuzumab

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | BEL

Facility Status City State Zip Country Details
Novartis Investigative Site Boston Massachusetts 02114 United States Details
Novartis Investigative Site Chapel Hill North Carolina 27514 United States Details
Novartis Investigative Site Philadelphia Pennsylvania 19111 United States Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site Saint Herblain cedex 44805 France Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Seoul Korea 03080 Korea, Republic of Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Valencia Comunidad Valenciana 46010 Spain Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Oxford OX3 7LJ United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field